Biometrics

Biometrics Optimization Solution (B.O.S)

Responding to ICH GCP E6(R2) and Oversight Requirements

Starting with a complete biometrics GAP analysis, to determine what steps to take to plan and implement your optimal data oversight strategy, we will work with you to develop a customized approach including processes, system selection and deployment and consistent data strategies.

As your partner, we’ll leverage our indication-specific experience to guide you through the full data management process, including:
  • Guaranteed ICH E6 (R2) Compliance
  • Integrated Risk Management Analysis & Mitigation
  • Improved Control of Data Acquisition, Storage & Reporting
  • All supported by a complete governance package to prove effective oversight and risk management

Why use B.O.S.?

Oversight is a requirement of the ICH E6(R2) addendum, according to which the ultimate responsibility for the quality and integrity of the trial data resides with the sponsor. This requires a risk-based approach to quality management and oversight. Conducting clinical data oversight can be challenging, particularly for companies that lack functional experts internally.

There are several ways to mitigate risks with an outsourcing model; using an experienced team through B.O.S. is both complete and cost-effective.

Why choose Alira Health?

The CROS NT and Alira Health biometrics team has provided expert statistical guidance for over 500 projects, including regulatory communication and submissions, study-based data management, biostatistics, and statistical programming. You will benefit from our:

  • Exceptional customer service and site relations
  • In-depth expertise across the entire clinical trial process
  • Flexible and tailored service delivered by multidisciplinary and global teams
  • Frequent, transparent, and professional communication
  • Guarantee we will lead your study efficiently, safely, and successfully

Related News

Publications July 11, 2023
Five Years Evolution of Chemotherapy Administration in Home Care in France
Have a look at the poster to get an overview of the dynamics in the development of chemotherapy in home care across different French regions during a five-year period.
Clinical France Outcomes Research
Events June 20, 2023
Advanced Wound Care Summit
We are pleased to announce that we will sponsor, attend, and speak at Advanced Wound Care Summit.
Clinical Clinical Trials Wound Healing
Events February 2, 2023
ACDM 2023
We are pleased to announce that we will be sponsoring and attending ACDM 2023. ACDM23 offers a full two-day program of expert speakers, specialist panels, workshops and debates which(...)
Clinical Data Science
Blog December 21, 2022
2022 Recap: Your Favorite Alira Health Publications
In 2022, the Alira Health team of scientists, strategists, economists, clinicians, and biostatisticians shared actionable insights, industry thought leadership, and leading-edge guidance(...)
Clinical Digital Health Market Access MedTech Pharma Regulatory
Blog December 14, 2022
How to Optimize Clinical Research with Patient Advisory Boards
Patient engagement is increasingly essential to all stages of product development—particularly clinical research.
Clinical Patient Advocacy Patient Centricity
Events November 30, 2022
Innovations in Wound Healing
We are excited to attend and sponsor a poster presentation at the Innovations in Wound Healing event this year. This unique meeting is led by a group of experienced educators, scientists(...)
Clinical Patient Centricity Wound Healing
Publications September 16, 2022
Analyzing and Interpreting Data from Biometric Monitoring Technologies in Clinical Trials
The rise of technology in clinical research allows us to capture meaningful aspects of health in clinical study participants.
Biometrics Clinical eCOA
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.